BIO-TECHNE Corp Operating Lease, Expense
BIO-TECHNE Corp (TECH) reported Operating Lease, Expense of $12.90 million for the 12-month period ending 2019-06-30, per its 10-K filed 2020-08-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2020-08-26
- BIO-TECHNE Corp operating lease, expense for fiscal 2019 was $12.90M, a 19.44% increase from fiscal 2018.
- BIO-TECHNE Corp operating lease, expense for fiscal 2018 was $10.80M, a 10.20% increase from fiscal 2017.
- BIO-TECHNE Corp operating lease, expense for fiscal 2017 was $9.80M.
| Period end | Operating Lease, Expense 12 month |
|---|---|
| 2019-06-30 | $12.90M 10-K · filed 2020-08-26 |
| 2018-06-30 | $10.80M 10-K · filed 2020-08-26 |
| 2017-06-30 | $9.80M 10-K · filed 2020-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |